Annolyse
BriefingsCompaniesScreenerInsightsPrinciplesCompareChatWatchlist

Explore

  • Briefings
  • Companies
  • Screener
  • Insights
  • Compare

Resources

  • Search
  • Methodology
  • API Reference

© 2026 Annolyse.

ChartsAnalysisChatData
  1. Charts
  2. Valuation
  3. Analysis
  4. Chat
  5. Data
  6. Sources
←Back to briefings
Synlait Milk (SML) / HY25

Result released24 March 2025·Annolyse analysis published23 April 2026

Synlait's 107.9% PBT rebound rests on a distorted, loss-making base

Revenue grew 40.4% and PBT rose 107.9%, but HY24's discontinued operation and negative tax rate make the comparison unreliable.

Primary Industries / Dairy processing

SML revenue trajectory

Revenue context before the current result.

↗
Loading chart...
HY25 was $916.8m, versus $652.9m in HY24.

SML EBITDA margin

EBITDA margin across covered periods.

↗
Loading chart...
  • HY22 SML HY: Outside range high ebitda margin. 8.7%; 5-period range -4.5% to 7.2%. EBITDA margin: 8.7%, above normal range; 5-period mean 3.9%, range -4.5%-7.2%.
EBITDA margin: 8.7%, above normal range; 5-period mean 3.9%, range -4.5%-7.2%.

SML operating cash flow

Operating cash flow across covered periods.

↗
Loading chart...
HY25 was -$12m, versus -$98.1m in HY24.

SML working-capital movement

Operating working-capital absorption or release by reporting period.

↗
Loading chart...
HY23 was $132.2m, versus -$70.8m in HY22.

Market context

Valuation

A close-dated read on what the market price implies next to the latest verified filing inputs. Unavailable metrics stay visible when the absence is useful context.

Prices as at close, 21 July 2026

Price and market cap

The latest close and share count context for the market price.

Market cap

$229.2m

i

End-of-day close multiplied by current shares on issue.

Profitability multiples

How the market price compares with recent earnings and cash-flow inputs.

P/E

Not available

i

Not available for this company right now.

EPS

Not available

i

Not available for this company right now.

PEG

Not available

i

Not available for this company right now.

EV/EBITDA

Not available

i

Not available for this company right now.

P/FCF

Not available

i

Not available for this company right now.

P/B

0.32x

i

Market value compared with latest reported equity.

Income and fund shape

Yield and fund-style valuation where the company shape supports it.

Dividend yield

0.0%

i

Trailing dividends compared with the latest close.

Total return

Not available

i

Available once dividend and adjustment data are verified.

Release date
24 March 2025
Published
23 April 2026
Ask about this result
Sections⌄
  1. Charts
  2. Valuation
  3. Analysis
  4. Chat
  5. Data
  6. Sources

Key metrics

Numbers worth scanning first

HY25 vs HY24

Revenue

$916.8m

Caveat: metric quality flags apply; use this value with basis context.

EBITDA

$63.1m

Caveat: metric quality flags apply; use this value with basis context.

Net profit after tax

$4.8m

Caveat: metric quality flags apply; use this value with basis context.

Net cash inflow from operating activities

−$12m

Caveat: metric quality flags apply; use this value with basis context.

Operating profit

$34.1m

Caveat: metric quality flags apply; use this value with basis context.

Profit before tax

$7.5m

Caveat: metric quality flags apply; use this value with basis context.

Cash and cash equivalents

$49m

+60.8% ↑ vs $30.5m

Total assets

$1.7b

Caveat: metric quality flags apply; use this value with basis context.

Analysis ofSML HY25·Result released24 March 2025·Annolyse analysis published23 April 2026

What changed

Synlait returned to profit, but the scale of the improvement is best read against a prior comparable half that included a discontinued operation and a $70.0m continuing-operations loss, so headline growth rates overstate underlying momentum

Revenue rose 40.4% to $916.8m, a level Annolyse's historical baseline classifies as unprecedented against a five-period mean of just 1.0% growth, which itself signals the comparison is not like-for-like. EBITDA lifted to $63.1m, about 3.2x the prior comparable period's $19.9m, while PBT moved from a $94.9m loss to a $7.5m profit (+107.9%) and NPAT swung from a $96.2m loss to $4.8m (+105.0%). Gross borrowings fell 25.2% to $440.9m and equity rose 14.0% to $796.7m.

What matters

Non-comparable base distorts headline growth

HY24 carried a $26.2m after-tax loss from a discontinued operation plus a deeply loss-making continuing business, so the 40.4% revenue and 107.9%/105.0% PBT/NPAT growth figures compare against a trough, not a normal period; this matters because investors reading these as organic momentum would overstate the run-rate improvement.

Tax line adds noise, not clarity. The effective tax rate was -35.9% versus -26.3% in the prior half, both unprecedented against a historical mean near 14.7%, meaning the 2.9 percentage-point PBT-to-NPAT growth gap reflects a tax credit rather than an operating swing; PBT is the cleaner read on the underlying turnaround.

Working-capital and cash signals are mixed. Inventory days fell to 68.9, below the historical range (mean 105.7 days), a favourable shift, while debtor days rose to 36.1, at the upper edge of the historical range (mean 33.7 days); inventories in dollar terms still grew 9.8% to $347.1m, which ties up cash even as days-on-hand improved.

Expectations

No stated targets or guidance figures were supplied for this half, so the result cannot be benchmarked against management's own commitments; the release notes EBITDA finished just above its earlier guidance range, but no numeric target was disclosed for comparison

Historical seasonality context shows HY24 contributed only 39.9% of FY24 revenue and, unusually, more than half (52.8%) of FY24's full-year NPAT loss came in the first half, meaning half-on-half shape has been erratic in recent years and this HY25 result should not be extrapolated to a full-year outcome without a second-half read.

Quality of result

Part of the turnaround looks durable: gross borrowings fell 25.2% and capex dropped 31.7% to $11.4m (1.2% of revenue), consistent with a genuine deleveraging effort rather than a one-period trick

However, operating cash flow remained negative at $12.0m and pre-lease free cash flow was still negative at $23.4m, so the reported NPAT of $4.8m was not backed by positive operating or free cash generation this half. Cash conversion improved from the prior comparable but the ratio itself is denominator-distorted given the small and volatile EBITDA and cash-flow bases, so it should not be read as a normal analytical signal in either period. The inventory-day improvement is encouraging for working-capital efficiency, but the rise in debtor days and the $30.8m increase in inventories on the balance sheet suggest some of the cash improvement is timing-related rather than fully structural.

Unresolved

Open questions

What is driving the negative effective tax rate, and is it expected to normalise toward the historical range in FY25?
How much of the net debt reduction reflects genuine cash generation versus asset sales or working-capital timing?
Will operating cash flow turn positive in the second half, given it remained negative this period despite the profit swing?
What are management's targets for FY25 EBITDA and NPAT, given none were disclosed in this release?
Is the rise in debtor days a one-off customer-mix effect or the start of a collection-cycle deterioration?

This briefing cannot assess whether the improved leverage and inventory metrics will hold through the second half, since no forward guidance or dividend policy detail was supplied.

Chat

Ask about SML HY25

Ask follow-up questions about Synlait Milk's HY25 result.

Informational only. No buy, sell, hold, price-target, or personal financial advice.

Ask about SML HY25

Informational only. No buy, sell, hold, price-target, or personal financial advice.

Sign in to chat

Sign in to ask questions about Synlait Milk's HY25 result.

What is driving the negative effective tax rate, and is it expected to normalise toward the historical range in FY25?Why does "Non-comparable base distorts headline growth" matter?How strong was the cash and earnings quality in HY25?What should I watch next for SML after HY25?

Checking account...

Data appendix

Show segment detail

Open to load segment breakdown.

Show analytical metrics

Open to load analytical metrics.

Show key metrics table

Open to load key metrics.

Sources

Current period

NZX Results Template

HY25 / results announcement↗

Synlait Half Year 2025 Announcement

HY25 / results release↗

Synlait Half Year 2025 Financial Statements

HY25 / financial report↗

Synlait Half Year 2025 Investor Presentation

HY25 / results presentation↗

Prior comparable period

NZX Results Template

HY24 / results announcement↗

Synlait Half Year 2024 Announcement

HY24 / results release↗

Synlait Half Year 2024 Financial Statements

HY24 / financial report↗

Full-year context

NZX Results Template

FY24 / results announcement↗

Synlait Full Year 2024 Annual Report

FY24 / financial report↗

Synlait Full Year 2024 Media Release

FY24 / media release↗

Release context

Announcement: Return to profitability with HY25 guidance provided

HY25 / commentary↗

Announcement: Synlait Annual Meeting 2024 Poll Results

HY25 / commentary↗

Announcement: Synlait HY25 results date and conference call details

HY25 / commentary↗

Annual Meeting Director Nominations

HY25 / commentary↗

Related insights

Cross-company views selected from the metrics in this briefing.

Earnings quality and statutory distortions

PBT and NPAT growth diverged by 2.9pp, with a distortion flag in the result.

→

Leverage and balance-sheet risk

Net debt / EBITDA is 6.20x for this result.

→

Revenue growth context

Revenue growth was 40.4% for this reporting period.

→

ROE and capital efficiency

ROE was 0.6%, +15.4pp versus the prior comparable period.

→
This briefing is based on available company filings and standard Annolyse calculations. It is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.

Get notified when SML publishes next

Get the next Synlait Milk briefing and related NZX reporting-season updates by email.